FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120404636> ?p ?o ?g. }

• W3120404636 abstract "Abstract Background The use of pyronaridine-artesunate (PA) has been associated with scarce transaminitis in patients. This analysis aimed to evaluate the hepatic safety profile of repeated treatment with PA versus artemether–lumefantrine (AL) in patients with consecutive uncomplicated malaria episodes in Bobo-Dioulasso, Burkina Faso. Methods This study analysed data from a clinical trial conducted from 2012 to 2015, in which participants with uncomplicated malaria were assigned to either PA or AL arms and followed up to 42 days. Subsequent malaria episodes within a 2-years follow up period were also treated with the same ACT initially allocated. Transaminases (AST/ALT), alkaline phosphatase (ALP), total and direct bilirubin were measured at days 0 (baseline), 3, 7, 28 and on some unscheduled days if required. The proportions of non-clinical hepatic adverse events (AEs) following first and repeated treatments with PA and AL were compared within study arms. The association of these AEs with retreatment in each arm was also determined using a logistic regression model. Results A total of 1379 malaria episodes were included in the intention to treat analysis with 60% of all cases occurring in the AL arm. Overall, 179 non-clinical hepatic AEs were recorded in the AL arm versus 145 in the PA arm. Elevated ALT was noted in 3.05% of treated malaria episodes, elevated AST 3.34%, elevated ALP 1.81%, and elevated total and direct bilirubin in 7.90% and 7.40% respectively. Retreated participants were less likely to experience elevated ALT and AST than first episode treated participants in both arms. One case of Hy’s law condition was recorded in a first treated participant of the PA arm. Participants from the retreatment group were 76% and 84% less likely to have elevated ALT and AST, respectively, in the AL arm and 68% less likely to present elevated ALT in the PA arm. In contrast, they were almost 2 times more likely to experience elevated total bilirubin in both arms. Conclusions Pyronaridine-artesunate and artemether–lumefantrine showed similar hepatic safety when used repeatedly in participants with uncomplicated malaria. Pyronaridine-artesunate represents therefore a suitable alternative to the current first line anti-malarial drugs in use in endemic areas. Trial registration Pan African Clinical Trials Registry. PACTR201105000286876" @default.
• W3120404636 created "2021-01-18" @default.
• W3120404636 creator A5005371655 @default.
• W3120404636 creator A5018877466 @default.
• W3120404636 creator A5024467013 @default.
• W3120404636 creator A5028327649 @default.
• W3120404636 creator A5036633224 @default.
• W3120404636 creator A5037217462 @default.
• W3120404636 creator A5037647381 @default.
• W3120404636 creator A5044655448 @default.
• W3120404636 creator A5046985654 @default.
• W3120404636 creator A5053380158 @default.
• W3120404636 creator A5062398556 @default.
• W3120404636 creator A5068293536 @default.
• W3120404636 creator A5087440676 @default.
• W3120404636 creator A5087512882 @default.
• W3120404636 date "2021-01-29" @default.
• W3120404636 modified "2023-10-15" @default.
• W3120404636 title "Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso" @default.
• W3120404636 cites W1827275786 @default.
• W3120404636 cites W1988201221 @default.
• W3120404636 cites W1995029436 @default.
• W3120404636 cites W2038101188 @default.
• W3120404636 cites W2064021654 @default.
• W3120404636 cites W2100200014 @default.
• W3120404636 cites W2100492116 @default.
• W3120404636 cites W2114213072 @default.
• W3120404636 cites W2114862397 @default.
• W3120404636 cites W2116415287 @default.
• W3120404636 cites W2118364911 @default.
• W3120404636 cites W2120622726 @default.
• W3120404636 cites W2128929477 @default.
• W3120404636 cites W2132423959 @default.
• W3120404636 cites W2137130305 @default.
• W3120404636 cites W2139242164 @default.
• W3120404636 cites W2141291954 @default.
• W3120404636 cites W2142960482 @default.
• W3120404636 cites W2149878679 @default.
• W3120404636 cites W2151099837 @default.
• W3120404636 cites W2157360098 @default.
• W3120404636 cites W2157912408 @default.
• W3120404636 cites W2160369357 @default.
• W3120404636 cites W2161859654 @default.
• W3120404636 cites W2169647488 @default.
• W3120404636 cites W2218985750 @default.
• W3120404636 cites W2465562385 @default.
• W3120404636 cites W2528937649 @default.
• W3120404636 cites W2607197422 @default.
• W3120404636 cites W2789297352 @default.
• W3120404636 cites W2794868066 @default.
• W3120404636 cites W4299363014 @default.
• W3120404636 doi "https://doi.org/10.1186/s12936-021-03593-6" @default.
• W3120404636 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7847156" @default.
• W3120404636 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33514368" @default.
• W3120404636 hasPublicationYear "2021" @default.
• W3120404636 type Work @default.
• W3120404636 sameAs 3120404636 @default.
• W3120404636 citedByCount "4" @default.
• W3120404636 countsByYear W31204046362021 @default.
• W3120404636 countsByYear W31204046362022 @default.
• W3120404636 countsByYear W31204046362023 @default.
• W3120404636 crossrefType "journal-article" @default.
• W3120404636 hasAuthorship W3120404636A5005371655 @default.
• W3120404636 hasAuthorship W3120404636A5018877466 @default.
• W3120404636 hasAuthorship W3120404636A5024467013 @default.
• W3120404636 hasAuthorship W3120404636A5028327649 @default.
• W3120404636 hasAuthorship W3120404636A5036633224 @default.
• W3120404636 hasAuthorship W3120404636A5037217462 @default.
• W3120404636 hasAuthorship W3120404636A5037647381 @default.
• W3120404636 hasAuthorship W3120404636A5044655448 @default.
• W3120404636 hasAuthorship W3120404636A5046985654 @default.
• W3120404636 hasAuthorship W3120404636A5053380158 @default.
• W3120404636 hasAuthorship W3120404636A5062398556 @default.
• W3120404636 hasAuthorship W3120404636A5068293536 @default.
• W3120404636 hasAuthorship W3120404636A5087440676 @default.
• W3120404636 hasAuthorship W3120404636A5087512882 @default.
• W3120404636 hasBestOaLocation W31204046361 @default.
• W3120404636 hasConcept C126322002 @default.
• W3120404636 hasConcept C141071460 @default.
• W3120404636 hasConcept C197934379 @default.
• W3120404636 hasConcept C203014093 @default.
• W3120404636 hasConcept C2776120307 @default.
• W3120404636 hasConcept C2777513400 @default.
• W3120404636 hasConcept C2778048844 @default.
• W3120404636 hasConcept C2778059366 @default.
• W3120404636 hasConcept C2778371730 @default.
• W3120404636 hasConcept C2778629330 @default.
• W3120404636 hasConcept C44249647 @default.
• W3120404636 hasConcept C71924100 @default.
• W3120404636 hasConcept C90924648 @default.
• W3120404636 hasConceptScore W3120404636C126322002 @default.
• W3120404636 hasConceptScore W3120404636C141071460 @default.
• W3120404636 hasConceptScore W3120404636C197934379 @default.
• W3120404636 hasConceptScore W3120404636C203014093 @default.
• W3120404636 hasConceptScore W3120404636C2776120307 @default.
• W3120404636 hasConceptScore W3120404636C2777513400 @default.
• W3120404636 hasConceptScore W3120404636C2778048844 @default.
• W3120404636 hasConceptScore W3120404636C2778059366 @default.
• W3120404636 hasConceptScore W3120404636C2778371730 @default.
• W3120404636 hasConceptScore W3120404636C2778629330 @default.

• next